Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts.…
Upstream Bio, Inc. (UPB) Reports Q3 Loss, Lags Revenue Estimates
Upstream Bio (NASDAQ: UPB) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 75 employees.
The shares were at 1.590 USD on 20 November 2026, down 93.6% over 52 weeks. Its 52-week range is 1.560 USD to 33.68 USD: the price is 95.3% below the high and 1.9% above the low.
Its market capitalisation is 87.15M USD.
Upstream Bio reports return on equity of -42.2% and revenue down 42.2% year over year.
It holds more cash than debt, a net cash position of 206.58M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. The next earnings report is expected on 25 March 2027.